Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Naoko, Kunami"'
Autor:
Toru Takata, Ai Mogi, Hidenori Sasaki, Naoko Kunami, Toshihiro Tanaka, Kazuo Tamura, Maki Goto, Yuta Nakashima, Yasushi Takamatsu, Atsushi Togawa
Publikováno v:
Annals of Oncology. 30:vi105
Background Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the standard treatment regimen for malignant lymphoma. CHOP-induced neutropenia is a common clinical complication that often develops into life-threatening febrile neutro
Autor:
Ryota Tsuchihashi, Tsuyoshi Ikeda, Kenji Ishitsuka, Naoko Kunami, Junei Kinjo, Masafumi Okawa, Hiroo Katsuya, Mio Kamikawa, Michika Matsuda, Daisuke Nakano, Yuka Yoshimura, Rumiko Nogami, Kazuo Tamura, Toshihiro Nohara
Publikováno v:
Journal of Natural Medicines. 67:415-420
Adult T-cell leukemia/lymphoma (ATL) is an incurable peripheral T-cell malignancy caused by human T-cell lymphotropic virus type I. In our preceding paper, 214 extracts from 162 plants were screened to elucidate the antiproliferative principles again
Publikováno v:
Anticancer research. 34(10)
Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of peripheral T-lymphocytes and its prognosis still remains very poor.The potential of combining the Bcl-2 homology 3 mimetic ABT-737, which blocks Bcl-2, Bcl-XL, and Bcl-w, with either
Autor:
Haruo Fujikane, Kentaro Ogata, Yasushi Takamatsu, Mana Fujita, Kenji Ishitsuka, Masanobu Uchiyama, Naoko Kunami, Kazuo Tamura, Tomona Toyota, Hiroo Katsuya, Masanao Ishizu, Shuuji Hara, Hidenori Sasaki
Publikováno v:
International Journal of Hematology. 92:762-764
Combination therapy with interferon-α and zidovudine (IFN/AZT) has been regarded as standard care for acute and indolent (i.e., chronic and smouldering) ATL based on reports involving a limited number of patients. This treatment approach has not bee
Autor:
Naoko, Kunami, Fusanori, Yotsumoto, Kenji, Ishitsuka, Tatsuya, Fukami, Takashi, Odawara, Sadao, Manabe, Toyokazu, Ishikawa, Kazuo, Tamura, Masahide, Kuroki, Shingo, Miyamoto
Publikováno v:
Anticancer research. 31(7)
The therapeutic outcome for T-cell acute lymphoblastic leukemia (T-ALL) remains poor; thus, novel, targeted therapies are urgently needed. Recently, we showed that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the E
Autor:
Naoko, Kunami, Yasushi, Takamatsu, Mana, Fujita, Hiroo, Katsuya, Hidenori, Sasaki, Shinichi, Wakamatsu, Kenji, Ishitsuka, Kazuki, Nabeshima, Kazuo, Tamura
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 51(6)
A 72-year-old man with extranodal natural killer cell lymphoma (ENKL) presented with a painless swelling of the left forearm. He was initially diagnosed as having a bacterial cellulitis and received antimicrobial therapy. However, his left arm became
Autor:
Hiroo Katsuya, Maki Goto, Ai Mogi, Kazuo Tamura, Toshihiro Tanaka, Yasushi Takamatsu, Eiichi Sato, Yuta Nakashima, Y. Ikari, K. Ishizuka, Masanao Ishizu, Naoko Kunami
Publikováno v:
Annals of Oncology. 23:xi147
Background Thymoma and thymic carcinoma are rare tumors. Due to their rarity, no optimal treatment has been determined. We report here on 11 such patients about their background characteristics, treatment strategy and its outcome. Methods We retrospe
Autor:
Naoki Mori, Kenji Ishitsuka, Kazuo Tamura, Shigeki Sawada, Fusanori Yotsumoto, Hiroo Katsuya, Chie Ishikawa, Masahide Kuroki, Naoko Kunami, Shingo Miyamoto, Hiroe Tanji, Morishige Takeshita
Publikováno v:
Cancer Research. 70:4524-4524
Adult T-cell lymphoma/leukemia (ATLL) is a T-cell malignancy caused by the human T-lymphotrophic virus type I (HTLV-I), and its therapeutic outcome still remains extremely poor. Therefore, novel therapeutic strategies are needed to improve treatment
Autor:
Naoki Mori, Fusanori Yotsumoto, Chie Ishikawa, Naoko Kunami, Hiroo Katsuya, Kazuo Tamura, Morishige Takeshita, Hiroe Tanji, Kenji Ishitsuka, Shingo Miyamoto, Shigeki Sawada
Publikováno v:
Blood. 114:1685-1685
Abstract 1685 Poster Board I-711 Adult T-cell lymphoma/leukemia (ATLL) is a T-cell malignancy caused by human T-lymphotrophic virus type I (HTLV-I), and its therapeutic outcome is still remains very poor. Therefore, novel therapeutic strategies are n